drugset / Trial / NCT00682383
Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)
NaSingle-groupOpen-labelPrevention
Summary
To determine the safety and efficacy of administering filgrastim with concurrent chemoradiotherapy and the potential benefit of administering pegfilgrastim with consolidation chemotherapy in patients with unresectable locally advanced NSCLC patients.
Timeline
- Start
- 2003-09
- Primary completion
- 2010-01
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegfilgrastim | Protein / enzyme biologic | 6 mg | Subcutaneous |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | — |
| Background | Etoposide | Small molecule | 80 mg/m2 | — |